Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
Ionis Pharmaceuticals stock last closed at $35.73, down 0.47% from the previous day, and has decreased 27.69% in one year. It has underperformed other stocks in the Biotechnology industry by 0.17 percentage points. Ionis Pharmaceuticals stock is currently +7.2% from its 52-week low of $33.33, and -34.37% from its 52-week high of $54.45.
At the moment, there are 157.9M IONS shares outstanding. The market capitalization of IONS is $5.64B. In the past 24 hours, 622,387 IONS shares were traded.
How to Buy Ionis Pharmaceuticals Stock
Wondering how to invest in Ionis Pharmaceuticals stock? Here's how.
Figure out where to buy Ionis Pharmaceuticals stock: You need to decide on an online brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you determine where to buy Ionis Pharmaceuticals stock.
Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
Fund your brokerage account: Choose your method of payment and add your details.
Research Ionis Pharmaceuticals stock: The Ionis Pharmaceuticals ticker symbol is IONS. Is Ionis Pharmaceuticals stock a good investment? Should you buy shares of IONS? How do IONS's underlying business fundamentals look? Do top analysts think Ionis Pharmaceuticals is a good buy? Why has IONS's stock price moved recently? (Hint: Our stock market analysis website can help you figure out if IONS is a good stock to buy).
Execute your IONS buy order: Decide if you will purchase IONS shares at the current market price or use a limit order to purchase IONS stock at a specific price.
Get the latest news on your investment in IONS: Create a watchlist to the latest updates on your investment in Ionis Pharmaceuticals stock.
Step 1: Figure out where to buy Ionis Pharmaceuticals stock
You will need a brokerage account to access the NASDAQ market and buy IONS shares.
A brokerage account enables you to buy and sell a variety of investments, such as stocks, bonds, mutual funds, and ETFs.
Our recommended brokerage: eToro
Based on our experience, eToro is the best brokerage. eToro gives you:
You can invest in stocks with zero commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
Access to global financial markets: From Technology to Healthcare, New York to London — you can fill your portfolio with stocks from the world's leading exchanges.
Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by creating an account with eToro today.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Create a brokerage account
Now that you've picked your brokerage, the next step is to fill out some personal information so you can invest in IONS today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Research Ionis Pharmaceuticals stock
Once you have decided on the best place to buy Ionis Pharmaceuticals stock, it's absolutely critical to evaluate their stock prior to investing, so you actually comprehend the risk and opportunity.
Ionis Pharmaceuticals quick stats
IONS Price
$35.73
1w %
5.06%
1y %
-27.69%
5y %
-44.14%
P/E
-14.64x
P/B
8.52x
P/S
6.61x
PEG
N/A
Revenue
$803.07M
Earnings
-$358.81M
Fore. Rev. Growth
6.17%
Fore. Earn. Growth
N/A
Market Cap
$5.64B
Next Earnings
N/A
Next Dividend
N/A
Ionis Pharmaceuticals Fundamentals
WallStreetZen was created to help average investors perform more accurate fundamental analysis quickly.
There are more short-term assets than long-term liabilities on the IONS balance sheet.
There are more short-term assets than short-term liabilities on the IONS balance sheet.
IONS has cash burn of 370885000. It has sufficient cash and short-term investments to cover this for at least one year.
IONS has $2.48B in cash and short term investments. This is sufficient to cover its annual cash burn of $370.89M.
Signs that IONS is not financially healthy:
IONS profit margin has gone up by 0.22 percentage points in the past year, but the company is still unprofitable.
IONS has a relatively high debt to equity ratio of 3.65.
Total IONS debt is higher than 5 years ago, relative to shareholder equity.
Do analysts think it's a good time to buy Ionis Pharmaceuticals stock
Out of 14 Equities analysts who track IONS, the consensus analyst rating on IONS is a Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they financial advice.
Most Recent IONS Analyst Recommendations
Jessica Fye, a top 11% analyst from JP Morgan maintains IONS with a hold rating and raises their IONS price target from $50.00 to $55.00, on Aug 26, 2024.
Salveen Richter, a bottom 14% analyst from Goldman Sachs maintains IONS with a strong sell rating and raises their IONS price target from $33.00 to $37.00, on Aug 2, 2024.
Gena Wang, a bottom 7% analyst from Barclays maintains IONS with a hold rating and raises their IONS price target from $45.00 to $51.00, on Aug 2, 2024.
Kostas Biliouris, a bottom 5% analyst from BMO Capital downgrades IONS to a hold rating and lowers their IONS price target from $67.00 to $60.00, on Aug 2, 2024.
Mani Foroohar, a bottom 2% analyst from Leerink Partners upgrades IONS to a buy rating and raises their IONS price target from $53.00 to $62.00, on Jul 24, 2024.
Last year, IONS revenue was $803.07M. Over the past 5 year, IONS's revenue has increased by -0.44% per year. This was slower than the Biotechnology industry average of 67.67%.
No, Ionis Pharmaceuticals doesn't provide an income stream by paying out dividends.
IONS Social Trading Data
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Execute your IONS buy order
You have two main types of orders:
Market order: A market order is an order to buy or sell a security at the best available price. Market orders are usually sufficient.
Limit order: A limit order is an order to buy or sell a security at a specific price (or better). If you want to be sure you're buying or selling at a specific price limit, use a limit order.
Click the Open button and eToro will place your order.
If you require more help investing in stocks on eToro, watch the how to video below:
How much does it cost to buy one Ionis Pharmaceuticals share?
As of Nov 29, 2024, it costs $35.73 to buy one share of Ionis Pharmaceuticals stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.28 shares of IONS.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.